Overexpression of MRP4 mediated the acquired docetaxel resistance, targeting MRP4 treatment which re-sensitized docetaxel-resistant prostate cancer cells to docetaxel chemotherapy (25). This evidence concerns the gene ABCC4 and prostate cancer.